While market jitters have kept some IPO candidates on the sidelines, biotechs continue to tap the public market, with two ...

Oct 9 (Reuters) - City Therapeutics on Friday said it is targeting a valuation of up to $956.3 million in its US initial public offering, as biotech companies press ahead with listings despite market ...

The latest installment in BioPharma Dive’s data visualization series features a look at the factors pressuring biotech stocks ...

Caribou Biosciences, the off-the-shelf cell therapy outfit that spun out of Nobel Laureate Jennifer Doudna’s lab in 2011, is ...

While biotech increasingly adopts AI for R&D, manufacturing bottlenecks constrain health innovation. AI and robotics have the ...

Caribou Biosciences is shutting down after failing to raise the money necessary to fund a late-stage clinical trial of its off-the-shelf CAR-T therapy for lymphoma.

WASHINGTON — A broad tariff on imported pharmaceuticals took effect at the end of September, and some biopharma companies and ...

Iambic Therapeutics is aiming for a $135 million IPO in net proceeds as the AI biotech looks to fund the clinical development ...

I may have beaten this subject to death over the last month or so, but I cannot resist, and will write about it again.However ...

Currently, SXTC is trading at $6.60, up 456.59%. VERAXA Biotech develops next-generation antibody-based cancer therapies, including BiTAC T cell engagers and bispecific antibody-drug conjugates.The ...

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...